ARDELYX INC (ARDX)       2.9385  +0.01 (+0.29%)

2.9385  +0.01 (+0.29%)

US0396971071 - Common Stock

ARDELYX INC2.9385

NASDAQ:ARDX (2/1/2023, 9:50:10 AM)+0.01 (+0.29%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-03 2022-11-03/amc Earnings (Next) 02-27 2023-02-27
Ins Owners 2.64% Inst Owners 36.24%
Market Cap 550.85M Shares 187.46M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 83.08
IPO 06-19 2014-06-19

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ARDX Daily chart

Company Profile

Ardelyx, Inc. is a biopharmaceutical company. The company is headquartered in Fremont, California and currently employs 86 full-time employees. The company went IPO on 2014-06-19. The firm focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. The firm's product pipeline includes IBSRELA (tenapanor), XPHOZAH, RDX013 Program, and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of hyperphosphatemia, a condition of elevated levels of phosphate in the blood, common among patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

Company Info

ARDELYX INC

34175 Ardenwood Blvd

Fremont CALIFORNIA 94555

P: 15107457047.0

CEO: Michael Raab

Employees: 86

Website: https://www.ardelyx.com/

ARDX News

News Image8 days ago - InvestorPlace7 A-Rated Stocks to Buy for Less Than $25

These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market.

News Image12 days ago - Market News VideoInteresting ARDX Put And Call Options For March 17thNews Image13 days ago - Seeking AlphaArdelyx files $250M securities offering (NASDAQ:ARDX)

Biopharmaceutical firm Ardelyx (ARDX) has filed to offer and sell up to a maximum aggregate offering price of $250M of its common stock, preferred stock, debt securities, warrants,...

News Image16 days ago - InvestorPlace5 Under-the-Radar Penny Stocks With 100% Upside Potential

Most experts will advise you to steer clear of under the radar penny stocks – and for good reason. However, keep an eye on these.

News Imagea month ago - Seeking AlphaAbbVie, Vertex, Genmab among accurate biotech picks at SA for 2022 (NYSE:ABBV)

Seeking Alpha contributors accurately predicted the 2022 bull run of AbbVie (ABBV), Vertex Pharma (VRTX), and Genmab (GMAB), sometimes even against the consensus. Read the full story here.

News Imagea month ago - Seeking AlphaArdelyx stock rises ~10% as FDA grants appeal for kidney disease drug, refiling planned

Ardelyx (ARDX) said a department of the U.S. Food and Drug Administration ((FDA)) granted an appeal to the agency's complete response letter which had rejected the company's...

ARDX Twits

Here you can normally see the latest stock twits on ARDX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example